Breaking News

Qualigen, Hande Sciences Partner to Scale-Up Mfg. for IND-Enabling Studies

Hande to provide process development and scale-up batches of material for Qualigen’s GLP toxicology studies for Orphan oncology candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Qualigen Therapeutics, Inc. a life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, has partnered with China-based Hande Sciences to conduct manufacturing scale-up activities to support the Company’s IND-enabling good laboratory practice (GLP) studies for its lead therapeutic program, QN-302.   Hande specializes in scale-up of small molecules therapeutics and is building a large...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters